Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma — ZUMA-14  

Refractory Large B-cell Lymphoma Clinical Trial

Official title: A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)

Status Completed

Clinical Trial Summary

The primary objective of this study is to estimate the efficacy of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma.

Clinical Trial Description

Following at least 24 months of assessments after axicabtagene ciloleucel infusion, participants will be asked to rollover to a separate long-term follow-up study (Study KT-US-982-5968). Participants will complete the remainder of the 15-year follow-up assessments in the KT-US-982-5968 study. ;

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, B-Cell
• Refractory Large B-cell Lymphoma

• NCT number: NCT04002401
• Study type: Interventional
• Source: Gilead Sciences
• Status: Completed
• Phase: Phase 2
• Start date: November 5, 2019
• Completion date: January 30, 2023